Search clinical trials for: M3814

Total 20 results

Merck KGaA, Darmstadt, Germany

Completed

Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Advanced Solid Tumors

Belgium, Netherlands, Denmark
Merck Sharp & Dohme LLC

Completed

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Effect of Food on Peposertib PK

Healthy

Germany
National Cancer Institute (NCI)

Suspended

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Lymph Nodes

United States
Merck Sharp & Dohme LLC

Completed

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

Parkinson's Disease
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Advanced Solid Tumors

United States, Germany, Norway, Netherlands, Belgium, Denmark, Sweden, Switzerland
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Study of Avelumab-M3814 Combinations

Solid Tumors | Oncology

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Malignant Solid Neoplasm | Cholangiocarcinoma | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Stage III Gallbladder Cancer AJCC v8 | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic...

United States
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)

Parkinsonian Disorders | Dyskinesia, Drug-Induced | Akathisia, Drug-Induced
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

Small Cell Lung Cancer

Belgium, Denmark, Italy, United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Romania, Spain, United Kingdom
National Cancer Institute (NCI)

Suspended

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

Locally Advanced Rectal Cancer

United States, Spain
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Neuroendocrine Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable Sarcoma

United States
Fundación Cardioinfantil Instituto de Cardiología
Instituto de Corazón de Bucaramanga

Unknown

A Trial Testing Amiodarone in Chagas Cardiomiopathy (ATTACH)

Chagas Cardiomyopathy

Colombia
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVA Lip and Oral... and other conditions

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)

Chronic Hepatic Impairment
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States

Search clinical trials for: M3814

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations